ELATATUG VEDOTIN
UNII W2SM42UUZ5

Substance Identification & Data

This profile provides standardized clinical and technical data for Elatatug Vedotin, uniquely identified by the FDA Unique Ingredient Identifier (UNII) W2SM42UUZ5.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3038456-01-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

W2SM42UUZ5

CAS Registry Number

3038456-01-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

ELATATUG VEDOTIN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C185565

National Cancer Institute reference terminology for clinical and research data.

INN ID

13747

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Elatatug Vedotin

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Elatatug Vedotin. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Elatatug Vedotin

Common Names & Synonyms

H-gamma1 heavy chain (1-448) [VH (Homo sapiens IGHV3-23*03 (91.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)],(221-220')-disulfide with L-kappa light chain (1'-220') [V-KAPPA Musmus/Homsap (Mus musculus IGKV8-19*01 (90.1%) -IGKJ4*01 (91.7%) S120>Q (106')/Homo sapiens IGKV4-1*01 (88.1%) -IGKJ2*02 (100%), CDR -IMGT [12.3.9] (27'-38'.56'-58'.95'-103')) (1'-113') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (159'), V101 (197')) (114'-220')]; dimer (227-227'':230-230'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of an average of four L -cysteinyl residues among 221, 227, 230, 220', 221'', 227'', 230'' and 220''' with (3RS)-1-(6-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(2S)-1-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl (vedotin) groups

Immunoglobulin G1, anti-(human claudin 18.2) (human-Mus musculus monoclonal TORL-2-307 γ1-chain), disulfide with human-Mus musculus monoclonal TORL-2-307 κ-chain, dimer, reduced, tetrakis(thioether) with N-[[[4-[[N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide

elatatug vedotin [INN]

immunoglobulin G1-kappa, anti-[Homo sapiens CLDN18 (claudin 18, claudin-18, surfactant associated protein J, SFTPJ) isoform 2], monoclonal antibody, conjugated on an average of four cysteinyl residues to vedotin, comprising a cleavable linker and monomethylauristatin E (MMAE) (elatatug vedotin)

External Clinical & Regulatory Resources

Previous UNIIW2SJ5WR9AK

Next UNIIW2SZ2EQN3L